34 citations
,
January 2000 in “Journal of Andrology” CAG repeat polymorphism and prostate zone volume are not reliable markers of long-term androgen sensitivity.
31 citations
,
January 1989 in “The Prostate/The prostate” Estradiol and castration reduced prostate cancer development in rats when applied at early stages, but were ineffective after cancer was established.
30 citations
,
June 2010 in “Endocrine Related Cancer” SRD5A1 is crucial in advanced prostate cancer, and blocking both SRD5A1 and SRD5A2 is more effective than targeting SRD5A2 alone.
30 citations
,
January 2008 in “The Aging Male” The study found no link between baldness patterns and androgen levels in men with benign prostate enlargement or prostate cancer.
29 citations
,
March 2010 in “Cancer epidemiology” Men who start losing hair at age 30 may have a lower risk of prostate cancer.
28 citations
,
June 2010 in “European Journal of Cancer” Baldness at age 40 is not linked to a higher risk of aggressive prostate cancer.
28 citations
,
January 2003 in “Urologic oncology” Suppressing certain hormones might help prevent prostate cancer.
21 citations
,
March 2013 in “Cancer Epidemiology, Biomarkers & Prevention” Early-onset baldness is linked to a higher risk of aggressive prostate cancer in African-American men, especially before age 60.
20 citations
,
March 2021 in “Cancers” Certain genetic variants increase the risk of aggressive prostate cancer.
20 citations
,
August 2020 in “Scientific Reports” Low-dose bisphenol A increases prostate size in rats by affecting certain enzymes.
18 citations
,
July 2015 in “Drug Healthcare and Patient Safety” Hormone therapy for prostate cancer can increase heart risks, especially in men with heart conditions.
17 citations
,
July 2016 in “The Prostate” Metformin may lower PSA levels, possibly affecting prostate cancer development.
17 citations
,
January 2016 in “American Journal of Epidemiology” Men with male pattern baldness have a higher risk of dying from prostate cancer.
17 citations
,
November 2012 in “Cancer Epidemiology, Biomarkers & Prevention” Early balding at 40 increases prostate cancer risk.
16 citations
,
August 2021 in “Tumor Biology” TMPRSS2 helps viruses enter cells and protects the prostate from inflammation-related cancer.
16 citations
,
April 2007 in “Journal of Obstetrics and Gynaecology Research” Prostate-specific antigen may be a new marker for excess male hormones in women with polycystic ovary syndrome.
14 citations
,
December 1998 in “The Journal of Clinical Endocrinology and Metabolism” MENT could be a better option than testosterone for male hormone therapy and birth control because it works well at lower doses and has fewer side effects on the prostate.
13 citations
,
August 1995 in “The Journal of Steroid Biochemistry and Molecular Biology” The activity of a specific rat enzyme in the prostate and epididymis is highly dependent on the acidity level.
12 citations
,
March 2023 in “The FASEB Journal” Platelet-rich plasma can improve erectile function in older individuals by reducing prostate enlargement.
12 citations
,
March 2013 in “Cancer Causes & Control” Early balding, especially frontal, increases prostate cancer risk; more research needed.
11 citations
,
June 2020 in “Biomedicines” % free PSA and urinary markers help better identify prostate cancer.
11 citations
,
April 2020 in “Andrology” Testosterone replacement therapy, especially intramuscular, raises PSA levels, but no overall link between PSA and testosterone was found except in non-BPH patients.
11 citations
,
March 2014 in “Journal of The European Academy of Dermatology and Venereology” Hair loss gene linked to prostate issues.
10 citations
,
October 2012 in “Andrology” Prostate cancer can progress even with low testosterone due to internal hormone production in the tumor.
9 citations
,
February 2022 in “Biomolecules” Drinking a lot of alcohol increases the risk of prostate cancer and can worsen the condition.
9 citations
,
November 2021 in “Infectious Agents and Cancer” Androgen deprivation therapy doesn't lower the risk of death from COVID-19 in prostate cancer patients.
9 citations
,
November 2018 in “Acta Clinica Belgica” Don't combine abiraterone and spironolactone for prostate cancer treatment as it may worsen the disease.
9 citations
,
July 2018 in “Medicine” Men with vertex baldness may have a higher risk of developing prostate cancer, but more research is needed to confirm this.
9 citations
,
September 2014 in “Cancer Epidemiology, Biomarkers & Prevention” Certain genetic variants in the androgen receptor are linked to higher PSA levels, potentially affecting prostate cancer screening outcomes.
9 citations
,
January 2014 in “Medical Hypotheses” Higher DHT in male baldness may protect against prostate cancer.